Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001241132 | SCV001414127 | uncertain significance | Cohen syndrome | 2024-11-18 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 2726 of the VPS13B protein (p.Ile2726Thr). This variant is present in population databases (rs189689493, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 966454). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt VPS13B protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002430026 | SCV002680064 | uncertain significance | Inborn genetic diseases | 2024-12-10 | criteria provided, single submitter | clinical testing | The c.8177T>C (p.I2726T) alteration is located in exon 45 (coding exon 44) of the VPS13B gene. This alteration results from a T to C substitution at nucleotide position 8177, causing the isoleucine (I) at amino acid position 2726 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Natera, |
RCV001241132 | SCV002082667 | uncertain significance | Cohen syndrome | 2020-03-30 | no assertion criteria provided | clinical testing |